| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1116: Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia |
|
Medicine details |
|
| Medicine name | obecabtagene autoleucel (Aucatzyl®) |
| Formulation | Intravenous infusion |
| Reference number | 4896 |
| Indication | For treating relapsed of refractory B-cell acute lymphoblastic leukaemia |
| Company | Autolus Therapeutics plc |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/11/2025 |
| NICE guidance | |